Preveceutical Medical Inc · CSE:PREV
Preveceutical Medical — Investor Presentation (February 2024)
32 slides from Preveceutical Medical's investor presentation, Feb 14, 2024
Slide 1: Corporate Presentation
CORPORATE PRESENTATION JANUARY 2024 CSE: PREV OTCQB: PRVCF FSE: 18H
Slide 2: Disclaimer
DISCLAIMER This presentation and its appendices (together the “Presentation”) have been prepared and delivered by PreveCeutical® Medical Inc. (“PreveCeutical” or the “Company”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H). The Presentation and its contents are strictly confidential and may not be reproduced
Slide 3: Corporate Overview
CORPORATE OVERVIEW Preventive health sciences company with corporate offices in Vancouver, Canada, and wholly owned subsidiary in Brisbane, Australia. Leveraging innovative science & technology to enhance natural products as novel targeted therapeutics in a diverse portfolio of R&D programs addressi
Slide 4: Pipeline Overview
PIPELINE OVERVIEW MEETING UNMET CLINICAL NEEDS 01. 02. 03. 04. Non-Addictive Dual Gene Cannabinoid BSV Peptide Analgesic Therapy Sol-Gel Delivery Program Non-Addictive Analgesic Targeting Type 2 Diabetes Nose-to-Brain Delivery of Targeting Cancer Peptidesfor Pain Management & Obesity Therapeutic Can
Slide 5: Market
MARKET Cannabinoid Sol-Gel Delivery BSV Peptide Program $116.2 Billion $140.5 Billion $365.99 Billion $106.0 Billion in 2020 in 2030 by 2030 by 2030 CNS Therapeutic Market Global Chronic Pain Market Global Market for Global peptide therapeutics Cancer Treatments market is expected to reach Non-Addic
Slide 6: Non-Addictive Analgesic
NON-ADDICTIVE ANALGESIC The research program commenced mid-2018, and is being led by PreveCeutical’s Chief Research Officer, Dr. Harendra Parekh, in collaboration with UQ School of Pharmacy’s pain & inflammation pharmacology expert, Associate Professor Peter Cabot. NON-ADDICTIVE ANALGESIC (DYNORPHIN
Slide 7: Non-Addictive Analgesic: Using the Body's Own Endogenous Pathways
NON-ADDICTIVE ANALGESIC USING THE BODY’S OWN ENDOGENOUS PATHWAYS Clinically Available Agents Body’s Endogenous Pain-Killing (such as “Morphine or Fentanyl”) Peptides (“Dynorphin”) Inherent development of tolerance, addiction, In response to pain and inflammation, the body depression etc., to ALL cli
Slide 8: Non-Addictive Analgesic
NON-ADDICTIVE ANALGESIC This is a very exciting and important program as we focus on engineering a novel class of drugs derived from our very own endogenous pain pathways... Our Two Australian provisional applications entitled, “A preliminary work has highlighted that by using our Cyclic Peptide”, w
Slide 9: Dual Gene Therapy
DUAL GENE THERAPY TARGETING TYPE 2 DIABETES & OBESITY Targeting the over-expression of a gene that drives the manifestation of insulin resistance and accumulation of fatty acids. Co-developing a Leveraging Smart siRNA and a Tissue Targeted Bio- responsive Carrier System, PreveCeutical has generated
Slide 10: Dual Gene Therapy: Targeting the Root Cause of Diabetes and Obesity
DUAL GENE THERAPY TARGETING THE ROOT CAUSE OF DIABETES AND OBESITY Total global health expenditure due to diabetes was estimated at 673 billion US dollars for 2015 and 802 billion US dollars for 2040. Over-expression of select genes (and their encoding proteins) drive the manifestation of insulin re
Slide 11: Dual Gene Therapy: Phases Through to Evaluation
DUAL GENE THERAPY PHASES THROUGH TO EVALUATION The multi-disciplinary team mapped the phases of the project FIRST ARM FINAL ARM Objective 1: Objective 4: Engineer a library of novel Smart-siRNA constructs against the gene Perform biodistribution studies of lead Smart-siRNA carrier implicated and ove
Slide 12: Diabetes Facts & Figures
DIABETES FACTS & FIGURES In 2021 6.7 million people died due to diabetes International Diabetes Federation estimates that there will be 642 million adults with diabetes by 2030, & 783 million by 2045
Slide 13: Dual Gene Therapy
“With diabetes, over-production of a particular protein molecule has been identified and purposed to be responsible for the key drivers of DUAL GENE THERAPY diabetes and obesity, starting patient on an inevitable journey of significant co-morbidity and increased rates of mortality. PreveCeutical’s g
Slide 14: Cannabinoid Sol-Gel Delivery
CANNABINOID A novel process for preparing insoluble drug-containing Sol-gels has been developed by Preveceutical’s Chief Research Officer, SOL-GEL DELIVERY Dr. Harendra Parekh. The Cannabinoid Sol-gel formulations belong to PreveCeutical®. NOSE-TO-BRAIN DELIVERY OF THERAPEUTIC NOTABLE CANNABINOIDS B
Slide 15: Cannabinoid Sol-Gel Delivery: Why Nose-to-Brain?
CANNABINOID SOL-GEL DELIVERY WHY NOSE-TO-BRAIN? 01 02 03 04 Direct Drug Delivery to Brain Challenges with Oral Route BBB Permeability Leverage Olfactory Pathway Patient outcomes of Rapid breakdown of Difficult to reach the brain Ideal pathway to deliver cannabis based CNS drugs enzymes in gut; incid
Slide 16: Cannabinoid Sol-Gel Delivery
CANNABINOID SOL-GEL DELIVERY “Sol-gel technology has certainly shown significant promise in laboratory testing at this point. Eventually, PreveCeutical® believes that the outcomes of its I would like to see this proprietary technology be Cannabinoid Sol-gel Program may be of value to companies inter
Slide 17: BSV Peptide Program
BSV PEPTIDE PROGRAM The peptides within scorpion venom are very complex molecules and challenging to manufacture. PreveCeutical’s research team redesigned the peptides so they could be manufactured in the lab, addressing notable supply chain problems. TARGETING CANCER PROGRESSION NOTABLE Developing
Slide 18: BSV Peptide Program: How the Lead Peptides Were Identified
BSV PEPTIDE PROGRAM HOW THE LEAD PEPTIDES WERE IDENTIFIED? Screening of the four peptides in an invasion assay model showed to have the ability to reduce the invasion potential in brain cancer cell types. 01. 02. 03. Screening of 4 lead peptides Disease Activity in In-vitro/ Cell-line Studies Invasi
Slide 19: BSV Peptide Program
BSV PEPTIDE PROGRAM "We are very excited with the results of the BSV PreveCeutical® is now accelerating the process of evaluating options on how best to progress the two program, and in particular with this lead peptide. Our lead peptide drug candidates, which may include plan is to utilize these re
Slide 20: Patents & Licencing Agreements
PATENTS & LICENCING AGREEMENTS PATENT FAMILY TABLE PATENT NAME COUNTRY FILING DATE PUBLICATION DATE PEPTIDES & USES THEREOF INTERNATIONAL 2022.11.18 2023.05.25 CYCLIC PEPTIDES & USES THEREOF INTERNATIONAL 2021.12.22 2022.06.30 CANNABINOID FORMULATIONS & INTERNATIONAL 2021.08.31 2022.03.03 METHODS OF
Slide 21: Patents & Licencing Agreements
PATENTS & LICENCING AGREEMENTS PATENT FAMILY TABLE PATENT NAME COUNTRY FILING DATE PUBLICATION DATE DISULFIDE BOND CONTAINING INTERNATIONAL 2018.07.26 2019.01.31 COMPOUNDS AND USES THEREOF AUSTRALIA 2022.12.15 2023.02.02 EUROPE 2018.07.26 2020.06.03 CANADA 2018.07.26 2019.01.31 USA 2023.05.11 2023.0
Slide 22: AI & ML
AI & ML ARTIFICIAL INTELLIGENCE & MACHINE LEARNING Accelerating PreveCeutical's Research with AI & Machine Learning NON-ADDICTIVE ANALGESICS BSV PEPTIDE PROGRAM » Utilizing AI-driven molecular docking and dynamic simulations to » Employing AI-based protein folding predictions and structure- identify
Slide 23: AI & ML
AI & ML ARTIFICIAL INTELLIGENCE & MACHINE LEARNING Accelerating PreveCeutical's Research with AI & Machine Learning DUAL GENE THERAPY FOR TYPE 2 DIABETES & OBESITY KEY OBJECTIVES » Leveraging AI algorithms to identify potent siRNA constructs, » Building a Custom Language Model for PreveCeutical. opt
Slide 24: PreveCeutical Team
PREVECEUTICAL TEAM Stephen Van Deventer Mak Jawadekar PhD - Chairman and Chief Executive Officer – President, Chief Science Officer and Director Mr. Van Deventer is an experienced businessman Dr. Jawadekar completed his Ph.D. in Pharmaceutics at and corporate director. Specializing in international
Slide 25: PreveCeutical Team
PREVECEUTICAL TEAM Linnéa Olofsson PhD Kathy Rokita CPA – Director – Director Dr. Olofsson is an accomplished biophysicist with 12 years of Ms. Rokita is a finance, operations, and strategey-focused laboratory research experience in academia, and 3 years executive having extensive experience with la
Slide 26: PreveCeutical Team
PREVECEUTICAL TEAM C. Evan Ballantyne Harry Parekh PhD, BSc Hons I – Director - Chief Research Officer Mr. Ballantyne has extensive executive leadership experience Based at the University of Queensland’s (UQ) Pharmacy and has spent the last 20 years as a public and private Australia Centre of Excell
Slide 27: PreveCeutical Team
PREVECEUTICAL TEAM Shawn Sadler Andrea Ortega – Head of Artificial Intelligence – Executive Assistant & Office Manager With a deep understanding of Data Management, AI Ms. Ortega is a professional currently studying commerce while Frameworks, Information Governance, and Machine Learning, gaining val
Slide 28: PreveCeutical Australia Team
PREVECEUTICAL AUSTRALIA TEAM PreveCeutical® has established a wholly- owned subsidiary in Brisbane, Queensland, Australia, to bolster their research and development interests. The Australian team, which will be led by Stephen Van Deventer, the Chief Executive Officer, will work closely with Dr. Harr
Slide 29: Research Collaborators
RESEARCH COLLABORATORS Dr. Rakesh Veedu is leading the Precision Nucleic Professor Grant Ramm is currently the head of the Acids Theranostics Group, as a McCusker Research Hepatic Fibrosis Laboratory and Coordinator of the Fellow with the Perron Institute for Neurological and Cell and Molecular Biol
Slide 30: Research Collaborators
RESEARCH COLLABORATORS Dr. Ajit Shetty Aditya Bahl Dr. Shetty has extensive pharmaceutical experience Mr. Bahl brings over 20 years of experience in leading commercial and supply chain operations pharmaceutical marketing and clinical as well as significant educational background development and is k
Slide 31: Partners
PARTNERS LJ THE UNIVERSITY 4 DUMOULIN OF QUEENSLAND MURDOCH IB) BLACK Ww AUSTRALIA UNIVERSITY a QIMR Berghofer orjffit i” ™% > Smythe eo Medical Research Institute IP Amplified RAS
Slide 32: Please Contact
Stephen Van Deventer info@preveceutical.com PLEASE Investor Relations CONTACT ir@preveceutical.com 1 (604) 416-7777
PreveCeutical Medical — Investor Presentation (February 2024) on 6ix